Spotlight on Japan
As the world’s second-largest pharma and medtech market, Japan has historically been an innovation center for the industry. But amid an evolving healthcare landscape, this collection of articles and interviews looks at what opportunities and challenges executives at life-sciences companies need to address.
Our Insights
Article
Understanding the opportunity in Japan’s biosimilar market
-
Despite a sluggish start, Japan’s biosimilar market looks set for accelerated growth. The country’s patient co-pay dynamic, financial...
Article
The rise and rise of medtech in Asia
-
How can medtech companies thrive in the world’s fastest-growing market?
Article
Change in the Japanese pharmaceutical market: Cradle of innovation or grave of corporate profits?
-
Understanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients....
Article
A more effective model for managing change in Japan could accelerate economic growth
-
A culturally attuned approach is required.
Article
Asia on the move: Five trends shaping the Asia biopharmaceutical market
-
Enthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s...
Article
The evolving role of medical affairs in Asia−Pacific: Three imperatives for pharmacos
-
Medical affairs is poised for a broader, more strategic role. However, leaders will need to ramp up new types of capabilities...
Article
The digital imperative for pharma companies in Japan
-
Five facts showing that companies should invest in digital customer engagement in Japan.
Article
The medtech opportunity for Japanese companies
-
A large-scale commitment to growth in healthcare technologies could be a key contributor to the Japanese economy.
Article
Elevating the impact of medical affairs in Japan
-
Recent research sheds light on the value of the medical channel and what it takes to have a high-performing medical-affairs organization....
External Voices
Interview
Building digital ecosystems in Japan
-
Two Merck Healthcare digital specialists explain their company’s transformation and the impact it has had on patients.
Interview
Leading change in the Japanese pharma market: Innovating for the future in an uncertain present
-
Jacques Nathan, president of Sanofi Japan, discusses what’s ahead for his changing sector.
Interview
What’s next for Japan’s pharma market
-
The president of Merck in Japan discusses how healthcare players in the country can capitalize on early detection rates and use...
Interview
From semiconductors to life sciences: Building a global business out of Japan
-
The president and CEO of JSR Corporation discusses the company’s plans to grow a global healthcare franchise building from...